Q-omics provides the consensus-scored PDE1B profile across patient tissues and cancer cell-line models. PDE1B expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, PDE1B is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, PDE1B RNA expression shows 25,576 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LUSC, KIRC, and GBM as cancer lineages where PDE1B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PDE1B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PDE1B survival associations across molecular data types. PDE1B RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PDE1B RNA expression–survival associations across cancer types. High PDE1B expression shows unfavorable associations in LUSC, STAD, OV, ACC and LAML, but favorable associations in UCS. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUSC as the clearest survival context for PDE1B RNA expression.
This table summarizes PDE1B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PDE1B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PDE1B shows lower tumor expression in KICH, LUAD, UCEC, BLCA and LUSC and higher tumor expression in KIRC. The KIRC box plot shows higher PDE1B RNA expression in tumor versus normal tissue (log2 FC = +1.443, t-test p < 0.001).
This table shows molecular features associated with PDE1B in patient tissues and cancer cell lines. In patient samples, PDE1B shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PDE1B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BONE.
